Maxim Ruban, Larisa Bolotina, Andrey Kaprin. "Efficacy and safety of a short-course (12-week) de-escalated neoadjuvant regimen (weekly paclitaxel/trastuzumab/pertuzumab) in early HER2-positive breast cancer: Interim analysis of a prospective study.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.599